№ files_lp_4_process_1_50374
File format: docx Character count: 2699 File size: 2355 KB
Supplementary scientific material presenting flow cytometry gating strategies, cytokine measurements, and phenotypic analyses of proliferating CD4+ T cells and regulatory T-cell populations in PBMC samples from young and older adults after stimulation with pneumococcal substrate-binding lipoproteins.
Document type: Supplementary scientific figures
Scientific field: Immunology
Experimental material: Peripheral blood mononuclear cells (PBMCs)
Cell type analyzed: CD4+ T cells and regulatory T cells (Tregs)
Proteins studied: AmiA, AliA, AliB, AliC, AliD
Experimental techniques: Flow cytometry gating strategy, CellTrace proliferation assay, cytokine measurement, viSNE clustering
Cytokines measured: IL-9, TNF, IL-6, IL-21
Markers analyzed: CD25, CD127, TIGIT, Helios, PD-1, CTLA-4, FoxP3
Population groups: Young adults (20–35 years) and older adults (60–75 years)
Sample size: 12 young donors and 12 older donors (cytokine and phenotype analysis); 5 donors for immunogenicity screening
Stimulation condition: Seven-day or six-day in vitro stimulation with substrate-binding lipoproteins, particularly AliB
Statistical analysis: Mann–Whitney U-test
Measured outcomes: T-cell proliferation, cytokine production, marker expression frequency and intensity
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Review 1: “Transient JAK/STAT Inhibition by Ruxolitinib Modulates Malaria-specific CD4+ T Cell Responses and Enhances Recall Immunity in Volunteers Experimentally Infected with Plasmodium Falciparum”
Year: 2023
Region / City: Not specified
Topic: Immunology, Malaria, Clinical Trials
Document Type: Research Review
Organization / Institution: Not specified
Author: Henrique Borges da Silva
Target Audience: Researchers, Clinicians
Period of Validity: Not specified
Approval Date: Not specified
Modification Date: Not specified
Differential response of HBV Envelope-specific CD4+ T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy
Note: Year
Supplementary Figure S5 Overview of GO Biological process pathways found enriched in A. CD4+ T cells (6 hrs), B. CD8+ T cells (6 hrs), C. monocytes (6 hrs) and D. neutrophils (4 hrs) after treatment with 0.2 μg/mL CD20-TCB.
Year: 2023
Region / City: N/A
Topic: Biological Research
Document Type: Supplementary Figure
Organization / Institution: N/A
Author: N/A
Target Audience: Researchers in Immunology
Period of Validity: N/A
Date of Approval: N/A
Date of Changes: N/A
Supplementary Figure 9. Distribution of immune features of M2 macrophages, TGF-β, plasma cells, and memory activated CD4+ T cells by BRAF V600E
Year: Not specified
Region / City: Not specified
Subject: Immune features, BRAF V600E mutation
Document type: Scientific figure
Author: Not specified
Target audience: Researchers in immunology
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Supplemental material and methods for CD4+ T cell activation and analysis with Tat protein
Year: 2026
Region / City: Not specified
Subject: Immunology, T cell response
Document type: Research supplementary methods
Institution: Miltenyi Biotec, R&D Systems, Life Technologies
Authors: Not specified
Target audience: Researchers in immunology and cellular biology
Experimental period: Not specified
Techniques: Flow cytometry, intracellular staining, RT-qPCR, cell culture
Cell type: Human CD4+ T cells, naïve CD4+ T cells
Proteins and reagents: Tat protein, anti-CD3/CD28 antibodies, cytokines (IL-2, TGFβ-1, IL-12, IL-4)
Equipment: BD FACScan, FACScanto II, Chromo4 qPCR System
Analysis software: BD Cell Quest Pro, FlowJo 8.8.3
Description: Research supplementary source detailing protocols for CD4+ T cell isolation, activation, intracellular staining, and quantitative PCR in the presence of Tat protein for experimental immunology studies.
Cytotoxic T-Cell Implantation & Genetic Modification in a Treatment for Lung Carcinoma
Year: 2023
Region / City: N/A
Topic: Lung Cancer Treatment, Immunotherapy
Document Type: Research Paper
Author: Ayush Chalishajar
Target Audience: Researchers, Medical Professionals, Academics
Period of Action: January 15th - March 19th
Approval Date: N/A
Date of Changes: N/A
NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors
Year: 2026
Region / City: International / Multiple research institutions
Subject: Cancer immunotherapy, tumor microenvironment
Document type: Supplementary scientific data
Institution: University of Southampton, Genkyotex SA, La Jolla Institute for Allergy & Immunology, University of Toronto, University of Kent
Authors: Kirsty Ford, Christopher J. Hanley, Massimiliano Mellone, Cedric Szyndralewiez, Freddy Heitz, Philippe Wiesel, Oliver Wood, Maria Machado, Monette Lopez, Anusha-Preethi Ganesan, Chuan Wang, Ankur Chakravarthy, Tim Fenton, Emma V. King, Pandurangan Vijayanand, Christian H. Ottensmeier, Aymen Al-Shamkhani, Natalia Savelyeva, Gareth J. Thomas
Target audience: Researchers in oncology and immunology
Data type: Figures, tables, and experimental results
Methods: Q-PCR, immunofluorescence, IHC, RNA sequencing, gene network analysis
Experimental models: Murine syngeneic tumors, TC1, MC38, 4T1, BALBneuT breast tumors
Treatment tested: NOX4 inhibition, TGF-β1 inhibition, αPD-1, αCTLA-4, macrophage depletion
Key focus: CAF-mediated CD8 T-cell exclusion, tumor growth modulation, immunotherapy response
Supplementary content: Figures S1–S6, Tables S1–S2
Clinical, morphologic, immunophenotypic, and genomic features of atypical T-cell infiltrates with original and revised diagnoses
Year: 2026
Region / City: Not specified
Document type: Supplemental table
Medical field: Hematology / Dermatology
Study population: Patients with atypical T-cell infiltrates
Sample type: Skin biopsies
Analysis methods: Immunohistochemistry, TCR PCR, clinical follow-up
Author / Institution: Not specified
Patient demographics: Age and sex specified for each case
Follow-up period: Up to 36 months
Diagnosis categories: Original and revised, including MF, SS, reactive infiltrates
Treatment history: Chemotherapy, brentuximab vedotin, methotrexate, topical steroids, SCT
Outcome: Clinical progression, response to treatment, NED status
Pralatrexate (Folotyn®) for Relapsed or Refractory Peripheral T-Cell Lymphoma: PBS Authority Required Listing Proposal, July 2017
Year: 2017
Country: Australia
Program: Pharmaceutical Benefits Scheme (PBS)
Section: Section 100 Highly Specialised Drugs Program
Regulatory Authority: Pharmaceutical Benefits Advisory Committee (PBAC)
Regulatory Agency: Department of Human Services
Drug Name: Pralatrexate
Brand Name: Folotyn®
Manufacturer: Mundipharma Pty Ltd
Dosage Form: Solution for intravenous infusion, 20 mg in 1 mL
Maximum Quantity: 80 mg
Indication: Relapsed or chemotherapy-refractory peripheral T-cell lymphoma
Target Population: Adult patients with relapsed or refractory peripheral T-cell lymphoma after first-line chemotherapy
Treatment Regimen: 30 mg/m² intravenous infusion weekly for six weeks followed by one week rest
Treatment Phases: Initial treatment; continuing treatment
Restriction Type: Authority Required (Private and Public Hospital)
Clinical Criteria: Relapsed or chemotherapy-refractory disease following front-line curative intent chemotherapy
Comparator Treatments: DHAP, brentuximab, gemcitabine-containing regimens, methotrexate, romidepsin, ESHAP, ICE
Outcome Measures: Overall survival, overall response rate, safety
Regulatory Status: Registered by the Therapeutic Goods Administration (TGA) in December 2014
Therapeutic Area: Oncology / Hematologic malignancies
Topics: AliB CD4+ T-Cell